Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 6/20 | 0.45 |
| ▸ | PPARA | Q07869 | 6/20 | 0.45 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.40 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5448702 | 0.87 | PPARG (0.48) | PPARGPPARAALDH1A1LMNA | |
| SCHEMBL5447478 | 0.85 | PTGDR2 (0.44) | PTGDR2L3MBTL1SLC6A3CXCR2PKM | |
| SCHEMBL31123647 | 0.80 | L3MBTL1 (0.58) | PPARGPPARAPTGDR2L3MBTL1CXCR2 | |
| SCHEMBL11274332 | 0.80 | L3MBTL1 (0.58) | PPARGPPARAPTGDR2L3MBTL1CXCR2 | |
| SCHEMBL4630498 | 0.80 | PPARG (0.55) | PPARGPPARAPTGDR2L3MBTL1PKM | |
| SCHEMBL5438157 | 0.80 | PPARG (0.49) | PPARGPPARAPTGDR2L3MBTL1CXCR2 | |
| SCHEMBL4631073 | 0.78 | PPARG (0.51) | PPARGPPARAPTGDR2L3MBTL1PKM | |
| SCHEMBL5440957 | 0.77 | PPARG (0.38) | PPARGPPARAPTGDR2L3MBTL1ALDH1A1 | |
| SCHEMBL25685760 | 0.76 | CXCR2 (0.57) | PPARGPPARAPTGDR2L3MBTL1SLC6A3 | |
| SCHEMBL27547400 | 0.73 | ALDH1A1 (0.50) | PPARGPPARAPTGDR2L3MBTL1CXCR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070015799-A1 | Glyoxalase inhibitors | CHROMA THERAPEUTICS LIMITED (GB) | 2007-01-18 | — | — | US | disclosed |
| US-20070015799-A1 | Glyoxalase inhibitors | CHROMA THERAPEUTICS LIMITED (GB) | 2007-01-18 | — | — | US | disclosed |
| US-20070015799-A1 | Glyoxalase inhibitors | CHROMA THERAPEUTICS LIMITED (GB) | 2007-01-18 | — | — | US | disclosed |
| EP-1622869-A1 | GLYOXALASE INHIBITORS | Chroma Therapeutics Limited (GB) | 2006-02-08 | — | — | EP | disclosed |
| WO-2004101506-A1 | GLYOXALASE INHIBITORS | CHROMA THERAPEUTICS LIMITED (GB) | 2004-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070015799-A1 | Glyoxalase inhibitors | GLO1, LOX, LOXL1 | PPARG 4267/4885PPARA 4574/4885PTGDR2 3212/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.